Расширенный поиск

Роль формотерола в лечении бронхиальной астмы

Полный текст:

Об авторе

А.В. Емельянов


Список литературы

1. Global initiative for asthma. NHLB / WHO Workshop Report. National Heart Lung Blood Institute, Publication number 95!3659. 2004. Chapter 7; 93-148.

2. Ueki J., Rhodes C.G., Hughes J.M.B. et al. In vivo quantification of pulmonary ƒ!adrenoceptor density in humans with (S)-11C-CGP12177 and PET. J. Appl. Physiol. 1993; 75: 559-565.

3. Qing F., Rahman S.U., Rhodes C.G. et al. ƒ-adrenergic receptors in vivo and lung function in drug!free asthmatic subjects. Am. J. Respir. Crit. Care Med 1997; 155: A855.

4. Barnes P. Beta-adrenergic receptors and their regulation. Am. J. Respir. Crit. Care Med. 1995; 152 (3): 838-860.

5. Johnson M. The ƒ-adrenoceptor. Am. J. Respir. Crit. Care Med. 1998; 158 (5, pt 3): 146-153.

6. Hall I.P. Beta-2 adrenergic receptor dysfunction and polymorphism in asthma. In: Rose B.D. ed Up To Date. Waltham, MA, 2006. 35-41.

7. Kotani Y., Nishimura Y., Maeda H., Yokoyama M. Beta2-adrenergic receptor polymorphisms affect airways respon! siveness to salbutamol in asthmatic. J. Asthma 1999; 36 (7): 583-590.

8. Liggett S.B. Polymorphism of the ƒ2-adrenergic receptor and asthma. Am. J. Respir. Crit. Care Med. 1997; 156 (4, pt. 2): 156-162.

9. Lima J.J., Thomasson D.B., Mohamed M.H. et al. Impact of genetic polymorphism of the beta2!adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmacol. 1999; 65 (5): 519-525.

10. Israel E., Drazen J.M., Liggett S.B. et al. The effect of polymorphisms of the beta (2)!adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. 2000; 162 (1): 75-80.

11. Lipworth B.J., Hall I.P., Aziz I. et al. Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short! and long-acting beta2-agonist therapy. Clin. Sci. 1999; 96 (3): 253-259.

12. Anderson G.P., Linden A., Rabe K.F. Why are long-acting beta-adreno!ceptor agonists long acting? Eur. Respir. J. 1994; 7 (3): 569-578.

13. Palmqvist M., Persson G., Lazer L. et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur. Respir. J.1997; 10 (11): 2484-2489.

14. Palmqvist M., Ibsen T., Mellen A., Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1999; 160 (1): 244-249.

15. Rosenborg J., Larsson P., Tenger K., Hallstrom G. Mass balance and metabolism of [3H] Formoterol in healthy men after combined i.v. and oral administration!mimicking inhalation. Drug Metab. Dispos. 1999; 27 (10): 1104-1116.

16. Handley D.A., Anderson A.J., Koester J., Snider M.E. New mellenium bronchodilators for asthma: single isomer beta agonists. Curr. Opin. Pulm. Med. 2000; 6 (1): 43-49.

17. Lotvall J., Mellen A., Arvidsson P. et al. Similar bronchodilation with formoterol delivered by aerolizer or turbuhaler. Can. Respir. J. 1999; 6 (5): 412-416.

18. Bartow R.A., Brogden R.N. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs. 1998; 55 (2): 303-322.

19. Ferrari M., Balestreri F., Baratieri S. et al. Evidence of the rapid protective effect of formoterol dry!powder inhalation against exercise!induced bronchospasm in athletes with asthma. Respiration 2000; 67 (5): 510-513.

20. Nightingale J.A., Rogers D.F., Barnes P.J. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am. J. Respir. Crit. Care Med. 1999; 159 (6): 1786-1790.

21. van Noord J.A., Smeets J.J., Raaijmakers J.A. et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur. Respir. J. 1996; 9 (8): 1684-1688.

22. Bench G., Lapidus R., Levine B.E. et al. A randomized, 12 week, double!blind, placebo!controlled study comparing formoterol dry powder inhaler with albuterol metered - dose inhaler. Ann. Allergy Asthma Immunol. 2001; 86 (1): 19-27.

23. Malimard M., Bourcereau J., Le Gros V. et al. Comparison between formoterol 12 microg b.i.d. and on!demand salbutamol in moderate persistent asthma. Respir. Med. 2001; 95 (1): 64-70.

24. Tatersfield A.E., Lofdahl C.G., Postma D.S. et al. Comparison of formoterol and terbutaline for asneeded treatment of asthma: a randomized trial. Lancet 2001; 357 (9252): 257-261.

25. Konermann M., Luck G., Rawert B., Pirsig W. Effect of the long-acting beta-2 agonist inhalant formoterol on quality of sleep of patients with bronchial asthma. Pneumologie 2000; 54 (3): 104-109.

26. Bouros D., Bachlitzanakis N., Kottakis J. et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur. Respir. J.1999; 14 (3): 627-632.

27. Kips J.C., O'Connor B.J., Inman M.D. et al. A long term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high dose budesonide in asthma. Am. J. Respir. Crit. Care Med. 2000; 161 (3, pt 1): 996-1001.

28. Juniper E., Svensson K., O'Burne P.M. et al. Asthma quality of life during 1 year of treatment with budesonide with and without formoterol. Eur. Respir. J. 1999; 14 (5): 1038-1043.

29. Pauwels R.A., Lofdahl C.G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET) international study group. N. Engl. J. Med. 1997; 337 (20): 1405-1411.

30. Barnes P.J. Scientific rationale for inhaled combination therapy with long!acting ƒ2-agonists and corticosteroids. Eur. Respir. J. 2002; 19: 182-191.

31. FitGerald J.M., Chapman K.R., Della Cioppa G. et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO / ODI Study Group. J. Allergy. Clin. Immunol. 1999; 103 (3, pt 1): 427-443.

32. Stahl E., Postma D.S., Svensson K. et al. Formoterol used as needed improves health!related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids. Respir. Med. 2003; 97 (9): 1061-1066.

33. Ind P.W., Villasante C., Shiner R.J. et al. Safety of for! moterol by Turbuhaled as reliver medication compared with terbutaline in moderate asthma. Eur. Respir. J. 2002; 20 (4): 859-866.

34. Kaik G., Kattakis I., Anagnostopoulou O. et al. Sequential flexible therapy with formoterol (Foradil) plus budesonide (Miflonide) versus a fixed combination of salmeterol and fluticasone (Seretide) in asthma self!management. Eur. Respir. J. 2002; 20 (suppl. 38): 388 s.

35. Barnes P. Effect of beta!agonists on inflammatory cells. J. Allergy. Clin. Immunol. 1999; 104 (2, pt 2): S.10-17.

36. Moore R.H., Khan A., Dickey B.F. Long-acting inhaled ƒ2-agonists in asthma therapy. Chest. 1998; 113 (4): 1095-1108.

37. Maneechotesuwan K., Essilfie-Quaye S., Meah S. et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest. 2005; 128 (4): 1936-1942.

38. Wallin A., Sandstorm T., Soderberg M. et al. The effect of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indicies in mild asthma. Am. J. Respir. Crit. Care Med. 1999; 159 (1): 79-86.

39. Aziz I., Wilson A.M., Lipworth B.J. Effect of once!daily for! moterol and budesonide given alone and in combination on surrogate inflammatory markers in asthmatic adults. Chest 2000; 118 (4): 1049-1058.

40. Overbeek S.E., Mulder P.G., Baelemans S.M. et al. Formoterol added to low!dose budesonide has no additional anti!inflammatory effect in asthmatic patients. Chest 2005; 128 (3): 1121-1127.

41. Centanni S., Carlucci P., Santus P. et al. Nonpulmonary effects induced by addition of formoterol to budesonide therapy in patients with mild or moderate persistent asthma. Respiration. 2000; 67 (1): 60-64.

42. Guhan A.R., Cooper S., Oborne J. et al. Systemic effects of formoterol and salmeterol: a dose!response comparison in healthy subjects. Thorax 2000; 55 (8): 650-656.

43. Cazzola M., Imperatore F., Salzillo A. et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrythmias and hypoxemia. Chest 1998; 114: 411-415.

44. Cazzola M., Matera M.G., Donner C.F. Inhaled beta2-adrenoreceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65 (12): 1595-1610.

45. Nelson H.S., Weiss S., Bleeker E.R. et al. The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006; 129 (1): 15-26.

46. Wolfe J., LaForce C., Friedman B. et al. Formoterol, 24 mg bid and serious asthma exacerbations. Similar rates compared with formoterol, 12 mg bid, with and without extra doses taken on demand, and placebo. Chest. 2006; 129 (1): 27-38.

Для цитирования:

Емельянов А. Роль формотерола в лечении бронхиальной астмы . Пульмонология. 2006;(4):116-122.

Просмотров: 33

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)